{"id":14989,"date":"2021-07-07T14:36:12","date_gmt":"2021-07-07T14:36:12","guid":{"rendered":"https:\/\/clinlabint.com\/?p=14989"},"modified":"2021-07-07T14:36:12","modified_gmt":"2021-07-07T14:36:12","slug":"iksuda-therapeutics-closes-47-million-financing-round","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/iksuda-therapeutics-closes-47-million-financing-round\/","title":{"rendered":"Iksuda Therapeutics closes $47 million financing round"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Iksuda Therapeutics closes $47 million financing round<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, has completed a US$47 million financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners. The funding will support the advancement of Iksuda\u2019s lead ADC assets and expansion of its payload and conjugation platform technologies.<\/h3>\n

<\/p>\n

Iksuda\u2019s lead pre-clinical candidate, IKS03, is a best-in-class CD19-targeted ADC candidate for B-cell cancers. The investment will enable progression of IKS03 to first-in-human phase clinical trials. It will also be used to accelerate Iksuda\u2019s earlier-stage programmes including IKS04 and IKS012 to IND filing.<\/p>\n

Iksuda\u2019s ADC programmes target tumours that currently have limited treatment options and high relapse rates. The company\u2019s drug development pipeline is centred on the improved safety and efficacy conferred by tumour activated, prodrug payloads in combination with stable conjugation technologies, including its proprietary novel PermaLink platform. Iksuda\u2019s research-stage pipeline utilises its proprietary Protein Alkylating (ProAlk) tumour-activated payload platform, recently licensed from G\u00f6ttingen University. The novel mode of action for the ProAlk tuneable payload series differs from the field\u2019s primary focus of intra- or DNA inter-strand cross-linking, conferring benefits against drug and tumour resistance mechanisms, and enabling the development of more powerful, more tolerable ADCs.<\/p>\n

Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: \u201cThis is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programmes and bring them to the clinic, whilst supporting our commercial growth. The funding not only reflects the potential of our technologies, but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.\u201d<\/p>\n<\/div><\/section>
\n